• 1
    Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 121.
  • 2
    Schmucker DL, Woodhouse K, Wang R et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 1990; 48: 36574.
  • 3
    George J, Byth K, Farrell GC. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol 1995; 50: 72730.
  • 4
    Hunt CM, Westerkam SR, Stave M, Wilson J. Human hepatic cytochrome P4503A activity in the elderly. Mech Ageing Dev 1992; 64: 18999.
  • 5
    Wynne HA, Cope E, Mutch E, Rawlins MD, Woodhouse KW, James OFW. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989; 9: 297301.
  • 6
    Woodhouse KW, Wynne HA. Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. Clin Pharmacokinet 1988; 15: 28794.
  • 7
    Marchesini G, Bua V, Brunori A et al. Galactose elimination capacity and liver volume in ageing man. Hepatology 1988; 8: 107983.
  • 8
    Bach B, Molholm-Hansen J, Kampriann JP, Rasmussen SN, Skorsted Z. Disposition of antipyrine and phenytoin correlated with age and liver volume in man. Clin Pharmacokinet 1981; 6: 38996.
  • 9
    Swift CG, Homeida M, Halliwell M, Roberts CJC. Antipyrine disposition and liver size in elderly. Eur J Clin Pharmacol 1984; 14: 14952.
  • 10
    Kinirons MT, O'Shea D, Downing TE et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993; 54: 6219.
  • 11
    Pollock BG, Perel JM, Altieri LP et al. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology. Psychopharmacol Bull 1992; 28: 1638.
  • 12
    Kinirons MT, Morike K, Shay S, Roden DR, Wood AJJ. Does selective inhibition of cytochrome P450s occur? Clin Res 1994; 42: 215A.
  • 13
    Vestal RE, Wood AJJ, Branch RA, Shand DG, Wilkinson GR. Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther 1979; 26: 815.
  • 14
    Twum-barina Y, Finnegan T, Habash AI, Cape RD, Carruthers SG. Impaired enzyme induction by rifampicin in the elderly. Br J Clin Pharmacol 1984; 17: 5957.
  • 15
    George G, Wynne H, Woodhouse K. The association of age with the induction of drug metabolising enzymes in human monocytes. Age Ageing 1990; 19: 3647.
  • 16
    Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly. Clin Pharmacokinet 1997; 33: 30212.
  • 17
    Loi CM, Parker BM, Cusack BJ et al. Ageing and drug interactions. III. Individual and combined effects of cimetidine and cimetidine and ciprofloxacin on theophylline metabolism in healthy male and female non-smokers. J Pharmacol Exp Ther 1997; 80: 62737.
  • 18
    Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996; 31: 4764.
  • 19
    O'Mahony MS, Woodhouse KW. Age, environmental factors and drug metabolism. Pharmacol Ther 1994; 61: 27987.
  • 20
    Anderson KE, Conney AH, Kappas A. Nutrition and oxidative drug metabolism in man: influence of dietary lipids, carbohydrate and protein. Clin Pharmacol Ther 1979; 26: 493501.
  • 21
    Kappas A, Anderson KE, Conney AH, Alvares AP. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clin Pharmacol Ther 1976; 20: 64353.
  • 22
    Vestal RE, Norris AH, Tobin JD, Cohen BH, Shock NW, Andres R. Antipyrine metabolism in man: influence of age, alcohol, caffeine and smoking. Clin Pharmacol Ther 1975; 18: 42532.
  • 23
    Pantuck EJ, Pantuck CB, Garland WA et al. Stimulatory effects of brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther 1979; 25: 8895.
  • 24
    Bailey DB, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 1: 2689.
  • 25
    Krauss J, Desmond O, Marshall JP et al. Effects of ageing and liver disease on disposition of lorazepam. Clin Pharmacol Ther 1978; 24: 4119.
  • 26
    Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Clin Pharmacokinet 1991; 21: 16577.
  • 27
    Kim RB, Leake B, Cvetkovic M et al. Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate co-transporting polypeptide) activity. J Pharm Exp Ther 1999; 291: 12049.
  • 28
    Kim RB, Fromm MF, Wandel C et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101: 28994.
  • 29
    Wardell C, Kim RB, Roden DM, Wood AJJ, Wilkinson GR. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000; 28: 65560.
  • 30
    Suzuki H, Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharmaceut Sci 2000; 12: 312.
  • 31
    Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99: 5527.
  • 32
    Sadeque AJ, Wandel C, He H, Shah S, Wood AJJ. Increased drug delivery to brain by P-glycoprotein. Clin Pharmacol Ther 2000; 68: 2317.
  • 33
    Steiger B, Meier P. Bile acid and xenobiotic transporters in liver. Curr Opin Cell Biol 1998; 10: 4627.
  • 34
    Witkowski JM, Miller RA. Increased function of P-glycoprotein in 7 lymphocyte subsets of ageing mice. J Immunol 1993; 150: 1296306.
  • 35
    Gupta S. P-glycoprotein expression and regulation. Drugs Aging 1995; 7: 1929.
  • 36
    Woodhouse KW, Wynne H, Baillie H et al. Who are the frail elderly? Q J Med 1988; 68: 5056.
  • 37
    William FM, Wynne H, Woodhouse KW, Rawlins MD. Plasma aspirin esterase: the influence of age and frailty. Age Ageing 1989; 18: 3942.
  • 38
    Yelland C, Summerbell J, Nicholson E, Herd B, Wynne H, Woodhouse KW. The association of age with aspirin esterase activity in human liver. Age Ageing 1991; 20: 168.
  • 39
    Summerbell J, Yelland C, Woodhouse K. The kinetics of plasma aspirin esterase in relation to old age. Age Ageing 1990; 19: 12830.
  • 40
    Wynne H, Cope LH, Herd MD, James OF, Woodhouse KW. The association of age and frailty with paracetamol conjugation in man. Age Ageing 1990; 19: 41924.
  • 41
    Wynne H, Yelland C, Cope LH, Boddy A, Woodhouse KW, Bateman DN. The association of age and frailty in the pharmacokinetics and pharmacodynamics of metoclopramide. Age Ageing 1993; 22: 3549.
  • 42
    Wynne HA, Cope LH, James OFW, Rawlins MD, Woodhouse KW. The effect of age and frailty upon acetanilide clearance in man. Age Ageing 1989; 18: 4158.
  • 43
    Groen H, Horan MA, Roberts NA, Gulaki RS, Milijkovic B, Jansen EJ. The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women. Clin Pharmacokinet 1993; 25: 13644.
  • 44
    Abou Hatab K, O'Mahony MS, Patel S, Woodhouse K. Relationship between age and plasma esterases. Age Ageing 2001; 30: 415.
  • 45
    O'Mahony MS, George G, Westlake H, Woodhouse K. Plasma aspirin esterase activity in elderly patients undergoing elective hip replacement and with fractured neck of femur. Age Ageing 1994; 23: 33841.
  • 46
    Abou-Hatab K, O'Mahony MS, Patel S, Carey D, Woodhouse K. Plasma esterase activities in young and old patients undergoing open inguinal hernia repair. Arch Gerontol Geriatr 2000; 31: 1938.
  • 47
    Abou-Hatab K, Ganeshalingham K, O'Mahony MS, Giurani F, Patel S, Woodhouse K. The effect of community-acquired pneumonia on plasma esterases in older people. Eur J Clin Pharmacol 2001; 57: 5560.